

Senate Bill No. 242—Senators Nguyen, Donate; Flores, Hansen, D.  
Harris, Ohrenschall and Stone

Joint Sponsors: Assemblymen Carter and Marzola

CHAPTER.....

AN ACT relating to controlled substances; requiring the Department of Health and Human Services to establish the Psychedelic Medicines Working Group to study certain issues relating to the therapeutic use of entheogens during the 2023-2024 interim; prescribing the membership and duties of the Working Group; and providing other matters properly relating thereto.

**Legislative Counsel’s Digest:**

This bill requires the Department of Health and Human Services to establish the Psychedelic Medicines Working Group to study certain issues relating to the therapeutic use of entheogens during the 2023-2024 interim. This bill defines “entheogen” to include, without limitation, psilocybin and psilocin. This bill also: (1) prescribes the membership and duties of the Working Group; and (2) requires the Department of Health and Human Services to submit a written report describing the activities, findings, conclusions and recommendations of the Working Group for transmittal to the 83rd Session of the Legislature.

EXPLANATION – Matter in *bolded italics* is new; matter between brackets ~~omitted material~~ is material to be omitted.

---

WHEREAS, Nevada has a high prevalence of adults with behavioral health conditions; and

WHEREAS, Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy and safety in the treatment of a variety of behavioral health conditions, including, without limitation, addiction, treatment-resistant depression, major depressive disorder, post-traumatic stress disorder and psychological distress relating to the end of life; and

WHEREAS, The United States Food and Drug Administration has determined that preliminary clinical evidence indicates that psilocybin may demonstrate substantial improvement over available therapies for treatment-resistant depression and major depressive disorder and has accordingly granted Breakthrough Therapy designation for treatment that uses psilocybin as a therapy for treatment-resistant depression and major depressive disorder; and

WHEREAS, Numerous state and local lawmaking bodies throughout the United States have already enacted or are currently considering legislation decriminalizing certain conduct by certain persons relating to psilocybin and psilocin; now, therefore



THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN  
SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:

**Sections 1-3.** (Deleted by amendment.)

**Sec. 3.5.** 1. The Department of Health and Human Services shall establish the Psychedelic Medicines Working Group to study certain issues relating to the therapeutic use of entheogens during the 2023-2024 interim. The Working Group must consist of:

(a) The Director of the Department of Health and Human Services or his or her designee;

(b) The Attorney General or his or her designee;

(c) The Director of the Department of Veterans Services or his or her designee;

(d) The President of the State Board of Pharmacy or his or her designee;

(e) One member appointed by the Majority Leader of the Senate;

(f) One member appointed by the Minority Leader of the Senate;

(g) One member appointed by the Speaker of the Assembly;

(h) One member appointed by the Minority Leader of the Assembly; and

(i) The following members appointed by the Governor, each of whom must be a bona fide resident of this State for not less than 1 year immediately preceding his or her appointment:

(1) One member who has received an honorable discharge from the Armed Forces of the United States and who has experience with the use of entheogens to address post-traumatic stress disorder;

(2) One member who is a psychiatrist, or a psychologist with clinical experience, and who:

(I) Is licensed to practice in this State; and

(II) Has experience treating patients who have an alcohol or other substance use disorder;

(3) One member who has experience treating post-traumatic stress disorder in a clinical setting;

(4) One member who has experience researching the therapeutic use of entheogens pursuant to a license issued by the Drug Enforcement Administration of the United States Department of Justice;

(5) One member who is a representative of a tribal government, as defined in NRS 239C.105, in this State;

(6) One member who is a representative of an organization that advocates for and provides education to the public regarding the therapeutic use of entheogens; and



(7) One member who is a representative of a law enforcement agency in this State.

2. The Working Group shall, during the 2023-2024 interim:

(a) Examine various entheogens to determine which entheogens may be beneficial for therapeutic use in reducing suicidal ideation and improving mental health, including, without limitation, through the use of entheogens in the treatment of post-traumatic stress disorder, substance use disorder, major depressive disorder or psychological distress relating to the end of life;

(b) Review federal, state and local laws and regulations concerning the therapeutic use of entheogens and identify any revisions to the laws and regulations of this State that may be necessary to enable entheogens to be used for therapeutic purposes in this State;

(c) Review existing and ongoing research on the therapeutic use of entheogens; and

(d) Develop a strategic, measurable and actionable plan to allow access to safe and affordable entheogens so that such entheogens may be used for therapeutic purposes.

3. The Director of the Department of Health and Human Services shall serve as Chair of the Working Group. The Attorney General or his or her designee shall serve as Vice Chair of the Working Group.

4. A majority of the members of the Working Group constitutes a quorum for the transaction of business, and a majority of those members present at any meeting is sufficient for any official action taken by the Working Group.

5. The Chair of the Working Group may appoint subcommittees composed of members of the public who have relevant experience or knowledge to consider specific issues or other matters relating to the therapeutic use of entheogens.

6. Each member of the Working Group:

(a) Serves without compensation; and

(b) While engaged in the business of the Working Group, is entitled to receive the per diem allowance and travel expenses provided for state officers and employees generally.

7. The Department of Health and Human Services shall provide the Working Group with such administrative support as is necessary to assist the Working Group in carrying out its duties pursuant to this section.

8. The Department of Health and Human Services shall, on or before December 31, 2024, prepare and submit a written report describing the activities, findings, conclusions and



recommendations of the Working Group to the Director of the Legislative Counsel Bureau for transmittal to the 83rd Session of the Legislature.

9. As used in this section, “entheogen” includes, without limitation, psilocybin and psilocin.

**Sec. 4.** This act becomes effective upon passage and approval.

